Business
Lexaria Receives New Patents
Total of 6 new granted patents received by Lexaria so far in 2023Lexaria now holds 34 granted patents world-wideKELOWNA, BC / ACCESSWIRE / June 20, 2023 /
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"Total of 6 new granted patents received by Lexaria so far in 2023Lexaria now holds 34 granted patents world-wideKELOWNA, BC / ACCESSWIRE / June 20, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces that it has received notifications of four new granted patents.Lexaria has been granted a new Canadian patent under our Patent Family #1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof. This is Lexaria's 18th patent in this Patent Family and our first patent for this Patent Family issued in Canada.Also in Canada, Lexaria has been granted a new patent under our Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof which was previously announced as \"allowed\" on April 20, 2023. This is Lexaria's second patent in this Patent Family, following a similar patent issuance in Australia in 2022.Lexaria has also been granted two new US patents under our Patent Family #21. The first being for Pharmaceutical Compositions and Methods for Treating Hypertension; and the second being for Compositions and Methods for Treating Hypertension, which was previously announced as \"allowed\" on April 20, 2023. Lexaria points out that one of these patent awards is specifically for pharmaceutical compositions while the other patent award is for non-pharmaceutical compositions, each of which reinforce Lexaria's commercial opportunities in the separate pharmaceutical and consumer markets.Lexaria believes these two hypertension-related patents could be of particular importance related to the Company's pursuit of utilizing DehydraTECH-CBD in relation to our expected upcoming FDA Investigational New Drug application. The outcomes of our completed HYPER-H21 series of hypertension studies were instrumental in achieving these patent grants. These are Lexaria's first and second granted patents in this Patent Family #21.The global cardiovascular drugs market was worth US$146.5 billion in 2022 and expected to reach $173.5 billion in 2026 and by geography, North America is the biggest market in the world making US patent protection a necessity in the pursuit of commercial markets.About Lexaria Bioscience Corp.Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, impro...